Company / Return on Assets (ROA)
Ultragenyx Pharmaceutical Inc. Return on Assets (ROA) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Assets (ROA)
-37.5%
FY2025
5-year range
-45.8% / -26.5%
FY2021-FY2025
Trend
+0.9%
vs FY2024
Sector context
#151 of 213
Health Care
What the data says
At -37.5%, Ultragenyx Pharmaceutical Inc.'s return on assets (roa) ranks #151 of 213 in the Health Care sector. Return on Assets (ROA) has increased for 3 consecutive years, from -45.8% in FY2022 to -37.5% in FY2025.
Based on SEC 10-K filings.
-37.5% in FY2025 with a 5-year CAGR of -26.3%.
Improved from -40.7% to -37.5% over the past 2 years.
Health Care sector context is included.
Return on Assets (ROA) over time
Growth rates
- 3-Year Change
- +8.2pp
- 5-Year Change
- -26.3pp
- 10-Year Change
- -
Sector benchmark
#151 of 213 in Health CareTop 71% of 213This company -37.5% Sector average -24.1%
▼
-55.5% below sector average
Key checks
Key Insights
- Ultragenyx Pharmaceutical Inc.'s return on assets (roa) has grown for 3 consecutive years.
- In FY2025, return on assets (roa) increased 0.9% year-over-year.
- Currently 13.4pp below the Health Care sector average.
- Peak return on assets (roa) was recorded in FY2016.
Company context
Key Data Points
- Altman Z-Score -2.91 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Assets (ROA)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -37.5% | +0.9% |
| FY2024 | -37.9% | +7.0% |
| FY2023 | -40.7% | +11.1% |
| FY2022 | -45.8% | -73.0% |
| FY2021 | -26.5% | -135.5% |
| FY2020 | -11.2% | +57.8% |
| FY2019 | -26.6% | +3.1% |
| FY2018 | -27.5% | +7.4% |
| FY2017 | -29.7% | -168.3% |
| FY2016 | -11.1% | +57.5% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026